Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants

Subhedar, N. V.; Ryan, S. W.; Shaw, N. J.
November 1997
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Nov1997, Vol. 77 Issue 3, pF185
Academic Journal
No abstract available.


Related Articles

  • Inhaled nitric oxide does not increase lipid peroxidation in preterm infants. Drury, J. A.; Nycyk, J. A.; Subhedar, N. V.; Shaw, N. J.; Cooke, R. W. I. // European Journal of Pediatrics;1998, Vol. 157 Issue 12, p1033 

    Presents a randomized controlled trial of treatment with inhaled nitric oxide (INO) therapy and intravenous dexamethasone in preterm infants at risk of developing chronic lung disease. Concern on the introduction of INO; Comparison of oxygenation index between infants in the INO group and...

  • Is nitric oxide effective in preterm infants? Subhedar, Nimish; Dewhurst, Chris // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Sep2007, Vol. 92 Issue 5, pF337 

    The article cites a study involving the efficacy of inhaled nitric oxide in preterm infants with respiratory failure. It presents an overview of randomized controlled trials which suggests that there is insufficient evidence concerning long-term safety and effective routine use of this inhalant....

  • A three year follow up of preterm infants after moderately early treatment with dexamethasone. Romagnoli, C.; Zecca, E.; Luciano, R.; Torrioli, G.; Tortorolo, G. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jul2002, Vol. 87 Issue 1, pF55 

    Objective: To assess the effect of moderately early postnatal dexamethasone treatment on growth and neurodevelopmental outcome in preterm infants. Methods: Thirty preterm infants enrolled in a randomised clinical trial to investigate the effectiveness of moderately early dexamethasone...

  • Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Jefferies, Ann L. // Paediatrics & Child Health (1205-7088);Dec2012, Vol. 17 Issue 10, p573 

    Postnatal corticosteroids have been used for prevention and treatment of neonatal chronic lung disease (CLD) (also know as bronchopulmonary dysplasia), a significant cause of mortality and morbidity in preterm infants. As both dexamethasone and hydrocortisone administration within the first...

  • Steroids in full term infants with respiratory failure and pulmonary hypertension due to meconium aspiration syndrome. da Costa, David Eustace; Nair, Arun Kumar; Pai, Mangalore Govind; Al Khusaiby, Saleh Mohammed // European Journal of Pediatrics;2001, Vol. 160 Issue 3, p150 

    Abstract Persistent pulmonary hypertension of the newborn (PPHN) due to meconium aspiration syndrome (MAS), has a high morbidity and mortality especially in centres with limited access to extra-corporeal membrane oxygenation or nitric oxide therapy. In such a setting, we conducted a pilot study...

  • Inhaled NO for Preterm Infants – Getting to Yes? Stark, Ann R. // New England Journal of Medicine;7/27/2006, Vol. 355 Issue 4, p404 

    The author reflects on the advantages of inhaled nitric oxide (NO) among preterm infants. Lung inflammation linked with mechanical injury may contribute to bronchopulmonary dysplasia among preterm infants. Reports showed that inhaled NO improved oxygenation in preterm infants with severe...

  • Inhaled Nitric Oxide in preterm infants: a systematic review and individual patient data meta-analysis. Askie, Lisa M.; Ballard, Roberta A.; Cutter, Gary; Dani, Carlo; Elbourne, Diana; Field, David; Hascoet, Jean-Michel; Hibbs, Anna Maria; Kinsella, John P.; Mercier, Jean-Christophe; Rich, Wade; Schreiber, Michael D.; Srisuparp, Pimol; Subhedar, Nim V.; Van Meurs, Krisa P.; Voysey, Merryn; Barrington, Keith; Ehrenkranz, Richard A.; Finer, Neil // BMC Pediatrics;2010, Vol. 10, p15 

    Background: Preterm infants requiring assisted ventilation are at significant risk of both pulmonary and cerebral injury. Inhaled Nitric Oxide, an effective therapy for pulmonary hypertension and hypoxic respiratory failure in the full term infant, has also been studied in preterm infants. The...

  • A risk-benefit assessment of drugs used for neonatal chronic lung disease. Sweet, D.G.; Halliday, H.L. // Drug Safety;May2000, Vol. 22 Issue 5, p389 

    Improvements in neonatal intensive care have resulted in more extremely low birthweight babies surviving who are at risk of developing chronic lung disease. The preterm lung is vulnerable as it is both structurally immature and deficient in surfactant and antioxidant defences. Mechanical...

  • Inhaled Nitric Oxide. Lasser, Elliott C. // New England Journal of Medicine;10/13/2005, Vol. 353 Issue 15, p1626 

    A letter to the editor is presented in response to the article "Inhaled Nitric Oxide for Preterm Infants: Who Benefits?," by R.J. Martin and M.C. Walsh.

  • What is new in ventilation strategies for the neonate? Greenough, Anne; Sharma, Atul // European Journal of Pediatrics;Oct2007, Vol. 166 Issue 10, p991 

    A large number of ventilation strategies are now available for the neonate. This review has focused on new information, that is, studies published since 2000 and the implication of their results for current clinical practice. Meta-analysis of randomised trials has demonstrated that assist...


Read the Article


Sign out of this library

Other Topics